BL Pharmtech Statistics

Total Valuation

BL Pharmtech has a market cap or net worth of KRW 20.82 billion. The enterprise value is 25.57 billion.

Market Cap	20.82B
Enterprise Value	25.57B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

BL Pharmtech has 8.90 million shares outstanding. The number of shares has increased by 0.78% in one year.

Current Share Class	n/a
Shares Outstanding	8.90M
Shares Change (YoY)	+0.78%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	27.52%
Owned by Institutions (%)	n/a
Float	6.45M

Valuation Ratios

The trailing PE ratio is 4.57.

PE Ratio	4.57
Forward PE	n/a
PS Ratio	1.75
PB Ratio	0.75
P/TBV Ratio	0.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	5.61
EV / Sales	2.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.76

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.22.

Current Ratio	0.78
Quick Ratio	0.43
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	-1.37
Interest Coverage	-3.71

Financial Efficiency

Return on equity (ROE) is -27.51% and return on invested capital (ROIC) is -4.05%.

Return on Equity (ROE)	-27.51%
Return on Assets (ROA)	-3.22%
Return on Capital (ROIC)	-4.05%
Revenue Per Employee	853.04M
Profits Per Employee	325.71M
Employee Count	14
Asset Turnover	0.18
Inventory Turnover	0.62

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +332.53% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+332.53%
50-Day Moving Average	475.40
200-Day Moving Average	486.50
Relative Strength Index (RSI)	92.46
Average Volume (20 Days)	1,084,502

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BL Pharmtech had revenue of KRW 11.94 billion and earned 4.56 billion in profits. Earnings per share was 510.56.

Revenue	11.94B
Gross Profit	8.76B
Operating Income	-3.41B
Pretax Income	-8.18B
Net Income	4.56B
EBITDA	-2.60B
EBIT	-3.41B
Earnings Per Share (EPS)	510.56

Full Income Statement

Balance Sheet

The company has 1.64 billion in cash and 6.11 billion in debt, giving a net cash position of -4.46 billion or -501.48 per share.

Cash & Cash Equivalents	1.64B
Total Debt	6.11B
Net Cash	-4.46B
Net Cash Per Share	-501.48
Equity (Book Value)	28.09B
Book Value Per Share	3,124.21
Working Capital	-1.56B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.19 billion and capital expenditures -1.25 billion, giving a free cash flow of -4.44 billion.

Operating Cash Flow	-3.19B
Capital Expenditures	-1.25B
Free Cash Flow	-4.44B
FCF Per Share	-499.22

Full Cash Flow Statement

Margins

Gross margin is 73.39%, with operating and profit margins of -28.55% and 38.18%.

Gross Margin	73.39%
Operating Margin	-28.55%
Pretax Margin	-68.46%
Profit Margin	38.18%
EBITDA Margin	-21.74%
EBIT Margin	-28.55%
FCF Margin	n/a

Dividends & Yields

BL Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.72%
Buyback Yield	-0.78%
Shareholder Yield	-0.78%
Earnings Yield	21.82%
FCF Yield	-21.33%

Stock Splits

The last stock split was on February 5, 2010. It was a forward split with a ratio of 1.1.

Last Split Date	Feb 5, 2010
Split Type	Forward
Split Ratio	1.1

Scores

BL Pharmtech has an Altman Z-Score of -1.55. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.55
Piotroski F-Score	n/a